Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PEN-866 is a potential agent for controlling early stage tumor growth for non-small cell lung cancer (NSCLC). PEN-866 is a novel esterase-cleavable conjugate of an HSP90i and a topoisomerase I inhibitor, SN-38
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 4,070.00 | |
50 mg | 10-14 weeks | $ 5,380.00 | |
100 mg | 10-14 weeks | $ 7,600.00 |
Description | PEN-866 is a potential agent for controlling early stage tumor growth for non-small cell lung cancer (NSCLC). PEN-866 is a novel esterase-cleavable conjugate of an HSP90i and a topoisomerase I inhibitor, SN-38 |
Molecular Weight | 879.95 |
Formula | C49H49N7O9 |
CAS No. | 1472614-83-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PEN-866 1472614-83-7 AS-3201 SX-3030 PEN866 PEN 866 Ranirestat inhibitor inhibit